(firstQuint)Study of MEDI 507 in the Treatment of Pediatric Patients.

 This is a Phase I, open-label dose escalation trial of MEDI-507 in pediatric SCT and BMT recipients with at least Grade II acute GvHD.

 All patients will receive steroid therapy and MEDI-507 for treatment of GvHD.

 Study of MEDI 507 in the Treatment of Pediatric Patients@highlight

To assess the safety of escalating dose levels of MEDI-507 in pediatric stem cell and bone marrow allograft recipients who have at least Grade II GvHD.

